PRF Technologies (PRFX) Net Equity Issued and Repurchased (2021 - 2023)

PRF Technologies (PRFX) posted quarterly Net Equity Issued and Repurchased of -$1.7 million for Q4 2023, down 200.0% on a QoQ basis from $1.7 million in Q3 2023.

PRF Technologies (PRFX) Net Equity Issued and Repurchased (2021 - 2023) Analysis & Trends

PRF Technologies (PRFX) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$1.7 million the latest figure, recorded in Q4 2023.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$1.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2023 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $4.0 million, up 196.3% from the prior year.
  • Net Equity Issued and Repurchased declined to -$1.7 million in Q4 2023 per PRFX's latest filing, from $1.7 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for PRFX reached as high as $6.0 million in Q1 2021 and fell as low as -$1.7 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 500,000.00
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 23.60 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 PRF Technologies 745,168.93 451,168.93 - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -1.70 Mn
Dec 31, 2023 -1.70 Mn
Sep 30, 2023 1.70 Mn
Sep 30, 2023 1.70 Mn
Dec 31, 2021 446,000.00
Dec 31, 2021 446,000.00
Sep 30, 2021 -446,000.00
Sep 30, 2021 -446,000.00
Mar 31, 2021 6.00 Mn
Mar 31, 2021 6.00 Mn